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BuOE and tBHQ reduces growth and viability of castrateresistant prostate cancer
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Abstract

Prostate cancer is the second leading cause of cancer-related death in men. 1020% of prostate cancer patients develop castration-resistant prostate cancer
(CRPC) The median survival for CRPC patients is 14 months following diagnosis 1.
CRPC can spread to local tissues like the bladder, lymph nodes, and rectum but will
also reach bone through distant metastasis. The metastasis of CRPC proves
difficult for clinicians to treat. Redox active compounds can reduce growth and
induce death of cancerous cells by the creation of ROS, which cannot be broken
down by cancerous cells. This allows treatments like radiation and chemotherapy to
be more effective in killing cancer.

Combination of tBHQ and BuOE reduces growth in CRPC
cells
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Background
One treatment for prostate cancer is androgen deprivation therapy (ADT). Due to
cancer’s ability to use androgens as fuel for growth, the end goal of ADT is to
decrease circulating testosterone with hope to reduce cancer cell proliferation and
induce apoptosis. Cancer cells can become resistant to ADT and signs of
progression are observed despite the “castrate” levels of androgen available. tertbutylhydroquinone, tBHQ, is an aromatic compound that is commonly used as a food
preservative due to its antioxidative capacity. At higher concentrations, tBHQ
becomes cytotoxic at the cellular level due to its ability to redox cycle into the volatile
metabolite tert-butyl-p-benzoquinone, tBQ. This cycling between tBHQ and tBQ also
creates superoxide, O2•– . BuOE is a SOD mimic manganese porphyrin that
scavenges O2•– and produces hydrogen peroxide. By nature, cancer cells have a
much lower tolerance to anti/pro-oxidant compounds compared to non-cancerous
cells. Non-cancerous cells can breakdown H2O2 into H2O and O2, while cancerous
cells are unable to perform this conversion; leading to reduced growth and cell death.
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Figure 1. Structures of compounds that induced toxicity in CRPC cells.
A. BuOE B. tBHQ C. tBQ

Figure 3. 24-hour treatment of high dose tBHQ
and BuOE reduces cell growth. A. Varying doses
of tBHQ showed reduced cell growth compared to
control; dtBHQ.15, 20, and 25 µm tBHQ coupled
with 1 µm BuOE reduces growth significantly. B.
Varying doses of dtBHQ had little to no effect on cell
growth. High doses of tBHQ alone and combination
with BuOE significantly reduced cell growth in PC3
cells. 50 µm tBHQ dose was implemented due to no
response at 25 µm tBHQ dose. C. No significant
change within dtBHQ and tBHQ doses on cell
growth. 20 and 25 µm tBHQ combined with 1 µM
BuOE reduced cell growth in C42B cells.

Discussion
Braeuning et al. have shown that tBHQ exerts cytotoxicity to cells via redox cycling and production
of superoxide molecules2. Previous studies have shown that MnTE-2-PyP, an extremely similar
SOD mimic manganese porphyrin, suppresses prostate cancer growth via intracellular H2O2
production3. We speculate that BuOE follows the same mechanism of H2O2 production in CRPC
cells. We speculate that BuOE can assist in cycling of tBQ back to tBHQ by reductases to induce
constant toxicity. We observed 2 odd interactions during this project. Firstly, tBHQ interacted with
MTT and created formazan yielding false positive results in heavily damaged cells. Secondly, we
saw reduced survivorship of dtBHQ control wells that neighbored tBHQ treated wells. Braeuning
et al. observed this in an experiment and discovered small amounts of tBQ in control wells
neighboring tBHQ treated wells. This phenomenon might be explained by the effect of tBHQ on
the Nrf2 signaling pathway2. An example of this interaction can be seen in the dtBHQ treated
22RV1 clonogenic survival data in Figure 2.

Conclusion and Future Directions
•

tBHQ doses alone have slightly reduced cell growth and viability in 22RV1, PC3,
and C42B cells

• Coupling high dose tBHQ (25 and 50 µm) with 1 µM BuOE significantly reduces
growth and viability in 22RV1, PC3, and C42B cells.
• Redox biology is crazy!
• Future implications: Identifying an optimal dose of tBHQ for PC3 cells, adding
radiation dosing after treatment of tBHQ and BuOE to see effect on viability, and
starting in vitro models.

Combination of tBHQ and BuOE reduces viability in CRPC
cells
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Hypothesis
We hypothesize that the combination of tBHQ and BuOE will reduce CRPC cell
growth and viability via cytotoxicity produced by oxidation of tBHQ and production
of H2O2.

Coupling BuOE with tBHQ reduces survivability
of CRPC cells
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Figure 5. Proposed mechanism that induces reduced growth and viability in CRPC.
Highly toxic tBQ is created by the oxidation of tBHQ, this process also produces
superoxide radicals. BuOE utilizes the superoxide radicals and produces hydrogen
peroxide molecules that are cytotoxic to cancerous cells.
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Figure 2. Clonogenic survivability of 22RV1 and C42B cells. BuOE reduces
survivability by 50% while coupling tBHQ with BuOE induced 100% reduction.

Figure 4. 24-hour treatment of tBHQ and BuOE
reduces cell viability. A. Both tBHQ and dtBHQ
had no effect on viability of 22RV1 cells.
Combination of 25 µm tBHQ with 1 µM BuOE
reduces cell viability by ~40%. B. Varying doses of
dtBHQ had little effect on PC3 viability. 25 and 50
µm tBHQ alone reduced viability by ~50%. Doses of
15, 20, 25, and 50 µm tBHQ with 1 µM BuOE
significantly reduced viability of PC3 cells.
C. B. Both varying doses of tBHQ alone and
combination with BuOE reduced viability. Highest
dose of dtBHQ (25 µm) reduced viability by ~20% in
C42B cells.
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